{"id":56667,"date":"2026-02-09T20:59:16","date_gmt":"2026-02-09T12:59:16","guid":{"rendered":"https:\/\/flcube.com\/?p=56667"},"modified":"2026-02-09T20:59:17","modified_gmt":"2026-02-09T12:59:17","slug":"zhongsheng-pharma-reports-positive-phase-iii-data-for-onradivir-pediatric-and-adolescent-influenza-trials","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56667","title":{"rendered":"Zhongsheng Pharma Reports Positive Phase III Data for Onradivir Pediatric and Adolescent Influenza Trials"},"content":{"rendered":"\n<p><strong>Guangdong Zhongsheng Pharmaceutical Co., Ltd<\/strong> (<strong><a href=\"https:\/\/www.google.com\/finance\/quote\/002317:SHE\">SHE: 002317<\/a><\/strong>) announced <strong>positive top-line results<\/strong> from <strong>two Phase III clinical studies<\/strong> evaluating <strong>onradivir<\/strong> in pediatric and adolescent influenza patients. The trials tested <strong>onradivir granules<\/strong> in children aged <strong>2-11<\/strong> versus <strong>Roche&#8217;s Tamiflu<\/strong>, and <strong>onradivir tablets<\/strong> in adolescents aged <strong>12-17<\/strong> versus placebo, addressing critical unmet needs in <strong>pediatric antiviral formulation<\/strong> and <strong>swallowing difficulty populations<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-milestones\">Clinical Trial Milestones<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Study<\/th><th>Onradivir Granules Trial<\/th><th>Onradivir Tablets Trial<\/th><\/tr><\/thead><tbody><tr><td><strong>Indication<\/strong><\/td><td>Uncomplicated influenza A<\/td><td>Uncomplicated influenza A<\/td><\/tr><tr><td><strong>Age Group<\/strong><\/td><td>2-11 years<\/td><td>12-17 years<\/td><\/tr><tr><td><strong>Control<\/strong><\/td><td>Tamiflu (oseltamivir phosphate dry suspension)<\/td><td>Placebo<\/td><\/tr><tr><td><strong>Enrollment<\/strong><\/td><td>120 participants<\/td><td>157 participants<\/td><\/tr><tr><td><strong>Formulation<\/strong><\/td><td>Granules (ease of administration)<\/td><td>Tablets (adolescent-appropriate)<\/td><\/tr><tr><td><strong>Primary Outcome<\/strong><\/td><td>Positive efficacy + favorable safety<\/td><td>Positive efficacy + favorable safety<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale-amp-formulation-innovation\">Strategic Rationale &amp; Formulation Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pediatric-Focused Development:<\/strong> Both trials designed specifically to <strong>facilitate medication use<\/strong> for children, adolescents, and patients with <strong>swallowing difficulties<\/strong>\u2014a historically underserved population in influenza treatment<\/li>\n\n\n\n<li><strong>Granule Formulation Advantage:<\/strong> <strong>Onradivir granules<\/strong> enable <strong>flexible dosing<\/strong> and <strong>ease of administration<\/strong> for young children unable to swallow capsules, directly competing with <strong>Tamiflu dry suspension<\/strong> in the pediatric market<\/li>\n\n\n\n<li><strong>Tablet Transition:<\/strong> <strong>Onradivir tablets<\/strong> for adolescents bridge the gap to adult formulations, supporting <strong>lifecycle management<\/strong> and <strong>patient continuum of care<\/strong> from childhood through adulthood<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-context-amp-market-positioning\">Competitive Context &amp; Market Positioning<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Strategic Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Tamiflu Head-to-Head<\/strong><\/td><td>Onradivir granules demonstrated <strong>non-inferior\/superior efficacy<\/strong> vs. Roche&#8217;s established standard of care<\/td><\/tr><tr><td><strong>Pediatric Influenza Market<\/strong><\/td><td>Significant commercial opportunity; children represent <strong>high-transmission population<\/strong> driving household prescribing<\/td><\/tr><tr><td><strong>Formulation Differentiation<\/strong><\/td><td>Granules address <strong>swallowing difficulties<\/strong> across age spectrum, including elderly and disabled populations<\/td><\/tr><tr><td><strong>China Antiviral Landscape<\/strong><\/td><td>Onradivir advances as <strong>domestic alternative<\/strong> to imported neuraminidase inhibitors, aligning with <strong>API localization<\/strong> priorities<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-amp-commercial-outlook\">Development &amp; Commercial Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Priority<\/th><th>Execution Plan<\/th><\/tr><\/thead><tbody><tr><td><strong>Regulatory Submission<\/strong><\/td><td>NDA filing to NMPA based on Phase III data package<\/td><\/tr><tr><td><strong>Formulation Strategy<\/strong><\/td><td>Market granules for pediatric\/swallowing-difficulty segments; tablets for adolescent\/adult transition<\/td><\/tr><tr><td><strong>Seasonal Positioning<\/strong><\/td><td>Target influenza seasonality with pre-stocking and hospital formulary placement<\/td><\/tr><tr><td><strong>Lifecycle Expansion<\/strong><\/td><td>Potential exploration in influenza B and high-risk patient populations<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding onradivir regulatory approval timelines, pediatric influenza market penetration, and competitive positioning against oseltamivir products. Actual results may differ due to NMPA review processes, pricing negotiations for pediatric antivirals, and seasonal influenza variability affecting commercial demand.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/\u4f17\u751f\u836f\u4e1a\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8\u4e00\u7c7b\u521b\u65b0\u836f\u6602\u62c9\u5730\u97e6\u9879\u76ee\u4e24\u9879III\u671f\u4e34\u5e8a\u8bd5\u9a8c\u83b7\u5f97\u9876\u7ebf\u5206\u6790\u6570\u636e\u7ed3\u679c\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u4f17\u751f\u836f\u4e1a\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8\u4e00\u7c7b\u521b\u65b0\u836f\u6602\u62c9\u5730\u97e6\u9879\u76ee\u4e24\u9879III\u671f\u4e34\u5e8a\u8bd5\u9a8c\u83b7\u5f97\u9876\u7ebf\u5206\u6790\u6570\u636e\u7ed3\u679c\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-e55bfe79-16fb-4589-a34d-a80caf59b522\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/\u4f17\u751f\u836f\u4e1a\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8\u4e00\u7c7b\u521b\u65b0\u836f\u6602\u62c9\u5730\u97e6\u9879\u76ee\u4e24\u9879III\u671f\u4e34\u5e8a\u8bd5\u9a8c\u83b7\u5f97\u9876\u7ebf\u5206\u6790\u6570\u636e\u7ed3\u679c\u7684\u516c\u544a.pdf\">\u4f17\u751f\u836f\u4e1a\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8\u4e00\u7c7b\u521b\u65b0\u836f\u6602\u62c9\u5730\u97e6\u9879\u76ee\u4e24\u9879III\u671f\u4e34\u5e8a\u8bd5\u9a8c\u83b7\u5f97\u9876\u7ebf\u5206\u6790\u6570\u636e\u7ed3\u679c\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/\u4f17\u751f\u836f\u4e1a\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8\u4e00\u7c7b\u521b\u65b0\u836f\u6602\u62c9\u5730\u97e6\u9879\u76ee\u4e24\u9879III\u671f\u4e34\u5e8a\u8bd5\u9a8c\u83b7\u5f97\u9876\u7ebf\u5206\u6790\u6570\u636e\u7ed3\u679c\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-e55bfe79-16fb-4589-a34d-a80caf59b522\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced positive top-line results from two Phase III&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,163,1197,399],"class_list":["post-56667","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-results","tag-roche","tag-she-002317","tag-zhongsheng-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Zhongsheng Pharma Reports Positive Phase III Data for Onradivir Pediatric and Adolescent Influenza Trials - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced positive top-line results from two Phase III clinical studies evaluating onradivir in pediatric and adolescent influenza patients. The trials tested onradivir granules in children aged 2-11 versus Roche&#039;s Tamiflu, and onradivir tablets in adolescents aged 12-17 versus placebo, addressing critical unmet needs in pediatric antiviral formulation and swallowing difficulty populations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56667\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zhongsheng Pharma Reports Positive Phase III Data for Onradivir Pediatric and Adolescent Influenza Trials\" \/>\n<meta property=\"og:description\" content=\"Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced positive top-line results from two Phase III clinical studies evaluating onradivir in pediatric and adolescent influenza patients. The trials tested onradivir granules in children aged 2-11 versus Roche&#039;s Tamiflu, and onradivir tablets in adolescents aged 12-17 versus placebo, addressing critical unmet needs in pediatric antiviral formulation and swallowing difficulty populations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56667\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-09T12:59:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-09T12:59:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56667#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56667\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zhongsheng Pharma Reports Positive Phase III Data for Onradivir Pediatric and Adolescent Influenza Trials\",\"datePublished\":\"2026-02-09T12:59:16+00:00\",\"dateModified\":\"2026-02-09T12:59:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56667\"},\"wordCount\":377,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial results\",\"Roche\",\"SHE: 002317\",\"Zhongsheng Pharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56667#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56667\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56667\",\"name\":\"Zhongsheng Pharma Reports Positive Phase III Data for Onradivir Pediatric and Adolescent Influenza Trials - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-09T12:59:16+00:00\",\"dateModified\":\"2026-02-09T12:59:17+00:00\",\"description\":\"Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced positive top-line results from two Phase III clinical studies evaluating onradivir in pediatric and adolescent influenza patients. The trials tested onradivir granules in children aged 2-11 versus Roche's Tamiflu, and onradivir tablets in adolescents aged 12-17 versus placebo, addressing critical unmet needs in pediatric antiviral formulation and swallowing difficulty populations.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56667#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56667\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56667#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zhongsheng Pharma Reports Positive Phase III Data for Onradivir Pediatric and Adolescent Influenza Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zhongsheng Pharma Reports Positive Phase III Data for Onradivir Pediatric and Adolescent Influenza Trials - Insight, China&#039;s Pharmaceutical Industry","description":"Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced positive top-line results from two Phase III clinical studies evaluating onradivir in pediatric and adolescent influenza patients. The trials tested onradivir granules in children aged 2-11 versus Roche's Tamiflu, and onradivir tablets in adolescents aged 12-17 versus placebo, addressing critical unmet needs in pediatric antiviral formulation and swallowing difficulty populations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56667","og_locale":"en_US","og_type":"article","og_title":"Zhongsheng Pharma Reports Positive Phase III Data for Onradivir Pediatric and Adolescent Influenza Trials","og_description":"Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced positive top-line results from two Phase III clinical studies evaluating onradivir in pediatric and adolescent influenza patients. The trials tested onradivir granules in children aged 2-11 versus Roche's Tamiflu, and onradivir tablets in adolescents aged 12-17 versus placebo, addressing critical unmet needs in pediatric antiviral formulation and swallowing difficulty populations.","og_url":"https:\/\/flcube.com\/?p=56667","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-09T12:59:16+00:00","article_modified_time":"2026-02-09T12:59:17+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56667#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56667"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zhongsheng Pharma Reports Positive Phase III Data for Onradivir Pediatric and Adolescent Influenza Trials","datePublished":"2026-02-09T12:59:16+00:00","dateModified":"2026-02-09T12:59:17+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56667"},"wordCount":377,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial results","Roche","SHE: 002317","Zhongsheng Pharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56667#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56667","url":"https:\/\/flcube.com\/?p=56667","name":"Zhongsheng Pharma Reports Positive Phase III Data for Onradivir Pediatric and Adolescent Influenza Trials - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-09T12:59:16+00:00","dateModified":"2026-02-09T12:59:17+00:00","description":"Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced positive top-line results from two Phase III clinical studies evaluating onradivir in pediatric and adolescent influenza patients. The trials tested onradivir granules in children aged 2-11 versus Roche's Tamiflu, and onradivir tablets in adolescents aged 12-17 versus placebo, addressing critical unmet needs in pediatric antiviral formulation and swallowing difficulty populations.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56667#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56667"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56667#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zhongsheng Pharma Reports Positive Phase III Data for Onradivir Pediatric and Adolescent Influenza Trials"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56667","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56667"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56667\/revisions"}],"predecessor-version":[{"id":56669,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56667\/revisions\/56669"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56667"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56667"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56667"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}